Zifanocycline
Modify Date: 2025-08-25 17:47:23
Zifanocycline structure
|
Common Name | Zifanocycline | ||
|---|---|---|---|---|
| CAS Number | 1420294-56-9 | Molecular Weight | 552.62 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C29H36N4O7 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of ZifanocyclineZifanocycline (KBP-7072) is a semisynthetic third-generation aminomethylcycline antibiotic that inhibits the normal function of the bacterial ribosome. Zifanocycline exhibits a broad spectrum of in vitro antibacterial activity against Gram-positive and Gram-negative bacteria, including many multidrug-resistant pathogens. Zifanocycline is available in both oral and injectable formulations. Zifanocycline can be used for the research of acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, and complicated intra-abdominal infections[1][2]. |
| Name | Zifanocycline |
|---|
| Description | Zifanocycline (KBP-7072) is a semisynthetic third-generation aminomethylcycline antibiotic that inhibits the normal function of the bacterial ribosome. Zifanocycline exhibits a broad spectrum of in vitro antibacterial activity against Gram-positive and Gram-negative bacteria, including many multidrug-resistant pathogens. Zifanocycline is available in both oral and injectable formulations. Zifanocycline can be used for the research of acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, and complicated intra-abdominal infections[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Zifanocycline (KBP-7072) demonstrates MIC90 values of <1 μg/ml across a range of pathogens, including typical and atypical pathogens associated with community-acquired bacterial pneumonia (CABP)[1]. |
| In Vivo | In Sprague-Dawley (SD) rats, beagle dogs, and CD-1 mice, KBP-7072 demonstrated a linear PK profile after the administration of single oral and i.v. and multiple oral doses. The oral bioavailability ranged from 12% to 32%. The mean time to maximum concentration (T max) ranged from 0.5 to 4 h, and the mean half-life ranged from approximately 6 to 11 h. The administration of oral doses in the fed state resulted in marked reductions in the maximum plasma concentration (C max) and the area under the concentration-time curve (AUC) compared with dosing in fasted animals. The mean bound fractions of KBP-7072 were 77.5%, 69.8%, 64.5%, 69.3%, and 69.2% in mouse, rat, dog, monkey, and human plasma, respectively[1]. KBP-7072 exhibits dose-dependent potent activity against selected methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) S. aureus strains over the dose range studied (0.25 to 64 mg/kg/6 h) in neutropenic murine pneumonia infection model[2]. |
| References |
| Molecular Formula | C29H36N4O7 |
|---|---|
| Molecular Weight | 552.62 |
| InChIKey | LBKXOQRVWDAQSX-OMBSCLNISA-N |
| SMILES | CN(C)c1cc(CN2CC3CC3C2)c(O)c2c1CC1CC3C(N(C)C)C(=O)C(C(N)=O)=C(O)C3(O)C(=O)C1=C2O |